{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"12.6","value":"1.58"}]}],"title":"At time of bone marrow harvest"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"44.3","value":"14.1"}]}],"title":"Day 60 post-transplant"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6","upperLimit":"50.1","value":"18.1"}]}],"title":"Day 180 post-transplant"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"31.8","value":"12.7"}]}],"title":"Day 360 post-transplant"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"description":"Myeloma lysate response that measures the T-cell response quantified as %CD3+/CFSE-low/IFN-gamma+.","dispersionType":"Full Range","groups":[{"description":"therapeutic autologous lymphocytes\n\ntherapeutic tumor infiltrating lymphocytes\n\nmelphalan\n\nautologous hematopoietic stem cell transplantation","id":"OG000","title":"MILs in Patients Undergoing an Autologous Peripheral SCT"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"At time of bone marrow harvest, Day 60 post-transplant, Day 180 post-transplant, and Day 360 post-transplant","title":"Anti-tumor Immune Responses","type":"SECONDARY","unitOfMeasure":"%CD3+/CFSE-low/IFN-gamma+"}